Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2021 Third quarter results announcement
We announced our third quarter results for the period ended 30 September 2021 on Wednesday 27 October.
Latest information
New GSK Investor update
Emma Walmsley, CEO, and other members of CET hosted a virtual investor update on Wednesday 23 June.
The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.
Nick Stone appointed SVP Head of Investor Relations
Nick Stone has been appointed Head of Investor Relations, effective 4 October 2021.
Nick joins from AstraZeneca, where he has been leading Investor Relations in Europe, the Americas, and Asia Pacific, along with the sustainability outreach programme. Prior to this, he spent fifteen years in the biopharmaceutical sector, including in the areas of Commercial, Business Development and Corporate Strategy.
A qualified lawyer, Nick will lead IR for New GSK, working closely with the Consumer Healthcare IR team under Sonya Ghobrial in the run-up to the planned separation in mid-2022.
Latest press releases
- GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children
- MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab)
- GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
Annual Report 2020
We published our Annual Report 2020 on 09 March 2021. View the summary and download the full report or individual sections.
Sign up for announcements
Sign up to receive email notifications when we publish a stock exchange announcement.